News
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
Tru Niagen® to debut at NHNE via a celebration press conference following the expo's opening ceremony LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen® at the major mainland China trade show, China...
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil
Brazil is the first Latin American country to now welcome Tru Niagen®, with a strategy focused on reaching both consumers and Health Care Practitioners (HCPs) LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct...
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
The "807" patent held under exclusive license covers compositions comprising NAD+ precursor nicotinamide riboside LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, announced the U.S. Patent &...
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
Total net sales of $16.7 million for the three months ended June 30, 2022 with $14.5 million from Tru Niagen® and gross margin of 60.0% for the quarter LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022....
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2022. The financial results will be reported in a press...
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
Webinar Featuring Dr. Charles Brenner LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that it will host a key opinion leader (KOL) webinar on the transforming benefits of nicotinamide riboside (NR) on Wednesday, July 20, 2022 at 11:00 am Eastern Time. The...
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
As a pioneer of nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex aims to raise awareness amongst industry leaders LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and...
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
Under the distribution agreement, all cross-border operations in the region will be transitioned to Sinopharm, with Sinopharm investments to amplify Tru Niagen® brand awareness, as a first step in ChromaDex's recently announced China Joint Venture agreement LOS...
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer's 22nd Annual Consumer Growth and E-Commerce Conference. The ChromaDex management team...
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea
Tru Niagen® enters the international market with digital cross-border launch strategy LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in South Korea. Juvenis is a Korean...